Europe FIT Market Set to Expand at 7.1% CAGR Through 2034 Amid Growing Adoption of Non-invasive Screening Technologies

The Europe fecal immunochemical test (FIT) market was valued at US$ 1.4 Bn in 2023 and is projected to reach more than US$ 2.9 Bn by 2034, advancing at a CAGR of 7.1% from 2024 to 2034. Rising awareness of colorectal cancer (CRC) screening, growing incidence of CRC among aging populations, government-backed screening initiatives, and increasing preference for non-invasive diagnostic procedures are expected to drive market expansion. Wider adoption of FIT across organized screening programs, hospitals, diagnostic centers, and homecare settings is further creating opportunities for manufacturers and diagnostic technology providers.

The increasing focus on early cancer detection is encouraging healthcare systems across Europe to adopt convenient and accurate screening technologies. FIT offers a non-invasive approach to detecting occult blood in stool and is increasingly favored over traditional guaiac fecal occult blood testing (gFOBT). At the same time, advances in automated analyzers, testing kits, and reagent technologies are improving laboratory efficiency and supporting broader deployment of FIT.

Review significant findings and insights from our report in this sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86308

Market Overview

Colorectal cancer remains a significant public health concern across Europe, strengthening the need for accessible and reliable screening technologies. FIT can identify small quantities of blood in stool with high sensitivity and specificity, enabling healthcare providers to identify individuals who may require further diagnostic evaluation. Unlike gFOBT, FIT is not affected by dietary changes, making it a more convenient screening option for patients and healthcare professionals.

European screening recommendations increasingly favor FIT as an important tool for CRC detection. Its ability to support risk-based referrals and reduce unnecessary colonoscopies can help healthcare systems improve resource allocation while lowering the burden associated with invasive diagnostic procedures. Guidelines such as those from the National Institute for Health and Care Excellence (NICE) have also reinforced the role of FIT in primary care referrals, particularly for patients presenting with symptoms.

Key Market Growth Drivers

Growing Awareness of Early Colorectal Cancer Detection

Increasing awareness of the importance of early CRC diagnosis is a major factor supporting the Europe fecal immunochemical test market. Aging populations and lifestyle-related risk factors are contributing to the burden of colorectal cancer, increasing demand for accessible screening solutions.

Patient preferences are also influencing screening practices. While colonoscopy remains an important diagnostic procedure, concerns about discomfort and invasiveness can discourage eligible individuals from undergoing screening. FIT provides a more convenient, non-invasive alternative for initial screening, helping healthcare systems improve participation rates and identify individuals requiring additional investigation.

Greater public education regarding CRC symptoms, screening eligibility, and the benefits of early detection is therefore expected to expand the addressable patient base for FIT.

Government-led Screening Programs Supporting Adoption

National screening programs and public health initiatives are strengthening demand for FIT across Europe. Governments and healthcare organizations are increasingly emphasizing population-level cancer prevention and early diagnosis, creating a favorable environment for standardized stool-based screening.

The European Commission's Beating Cancer Plan has also emphasized improving cancer prevention and screening coverage. Such initiatives can encourage wider adoption of established screening technologies and improve access among eligible populations.

Shift Toward Non-invasive Screening Technologies

The non-invasive nature of FIT is a significant advantage in CRC screening. Patients can collect stool samples without undergoing an invasive clinical procedure, improving convenience and potentially increasing participation in screening programs.

FIT also provides healthcare providers with a practical method for identifying patients who may benefit from further investigation, helping optimize colonoscopy resources and potentially reducing unnecessary procedures.

Kits & Reagents Remain Central to FIT Testing

The Europe fecal immunochemical test market can be segmented into kits & reagents, analyzers, and others. Among these, kits & reagents represent a key product category because they contain the essential components required to perform FIT accurately and consistently.

These products typically include reagents, buffer solutions, collection components, and test materials required to identify occult blood in stool samples. Increasing screening volumes are expected to sustain demand for consumables alongside the expansion of automated testing infrastructure.

The growing importance of CRC screening among older populations further supports the requirement for dependable FIT kits and reagents. Manufacturers that can provide reliable, easy-to-use, and scalable testing solutions are positioned to benefit from the continued expansion of organized screening programs.

Hospitals & Diagnostics Centers Lead End-user Adoption

Hospitals & diagnostics centers are expected to maintain a leading position in the Europe FIT market based on end-user. These facilities benefit from established healthcare infrastructure, trained personnel, laboratory capabilities, and access to complementary diagnostic services.

The ability to integrate FIT into broader diagnostic workflows makes hospitals and diagnostic centers important points of testing. Insurance coverage, healthcare-provider referrals, and established screening programs can further support their continued dominance.

At the same time, homecare settings are emerging as a high-potential segment. Home-based sample collection can provide greater convenience for older adults, individuals with mobility limitations, and patients who may be reluctant or unable to visit healthcare facilities frequently.

The combination of institutional testing capacity and growing home-based screening is expected to broaden access to FIT throughout Europe.

Regional Outlook

Germany to Maintain Leading Position

Germany is expected to remain a prominent country in the European FIT landscape. The country's substantial colorectal cancer burden and established healthcare infrastructure create favorable conditions for the adoption of CRC screening technologies.

CRC represents a major cancer burden among both men and women in Germany, strengthening the importance of early detection and population screening. Clinical guidelines, professional training, quality initiatives, and organized screening systems are contributing to greater awareness of CRC prevention and diagnosis.

Across Europe, national screening programs are also strengthening the role of FIT in preventive healthcare. Continued efforts to standardize screening practices, expand eligible population coverage, and improve public awareness are expected to support sustained market growth.

Analysis of Key Players

The Europe fecal immunochemical test market features a competitive mix of diagnostic companies, laboratory technology providers, and specialized healthcare manufacturers. Companies are focusing on product development, automation, partnerships, and expansion of their diagnostic portfolios to strengthen their market positions.

Prominent companies profiled in the market include:

• Abbott Rapid Diagnostics
• Una Health
• Alpha Laboratories Ltd
• BIOHIT HealthCare Ltd
• Sysmex UK
• MAST Group Ltd
• Epigenomics AG
• Alfresa Pharma Corporation
• Aidian Oy
• Minaris Medical
• Immundiagnostik AG
• Sentinel Diagnostics
• Eiken Chemical Co. Ltd
• BTNX Inc.
• R-Biopharm
• Other Prominent Players

Key Player Strategies & Developments

Advancements in Automated FIT Testing

Diagnostic companies are increasingly developing automated systems designed to process larger numbers of FIT samples while minimizing manual intervention. Automation can improve laboratory productivity, reduce handling-related errors, and support the growing volume of population-based screening.

Sentinel Diagnostics Expands Automated Testing Capabilities

In June 2022, Sentinel Diagnostics introduced the SENTiFIT 800 Analyzer, a high-throughput automated instrument designed for fecal immunochemical testing. The system can process up to one million tests annually and is compatible with Sentinel's FOB Gold and CALiaGold test lines, supporting more efficient laboratory workflows.

Development of Next-generation Colorectal Cancer Screening

In November 2022, researchers from Hospital Clínic-IDIBAPS and CIBER developed miRFec, a fecal test intended for colorectal cancer screening. A Japanese company subsequently supported plans for multicenter clinical research evaluating the technology alongside FIT. Such developments illustrate the broader movement toward improving non-invasive colorectal cancer screening.

Market Challenges & Opportunities

Challenges

Patient Awareness Gaps: Despite growing recognition of CRC screening, inadequate understanding of stool-based tests can limit participation among eligible populations.

Preference for Invasive Diagnostic Procedures in Certain Cases: Positive FIT results generally require further clinical assessment, often involving colonoscopy, which may discourage some individuals from participating in screening.

Variation in National Screening Programs: Differences in healthcare policies, reimbursement frameworks, screening eligibility, and program implementation across European countries can create uneven adoption.

Opportunities

Expansion of Home-based Screening: Increasing use of homecare and at-home sample collection can improve access for elderly, mobility-limited, and geographically underserved populations.

Automation and High-throughput Testing: Advanced analyzers capable of processing large testing volumes offer opportunities for laboratories to improve efficiency and support population-wide screening programs.

Growing Investment in Early Cancer Detection: Continued government and private-sector investment in preventive healthcare and cancer screening is expected to create opportunities for FIT manufacturers and diagnostic technology developers.

Europe Fecal Immunochemical Test (FIT) Market Segmentation

By Product Type

• Kits & Reagents
• Analyzers
• Others

By End-user

• Hospitals & Diagnostics Centers
• Specialty Clinics
• Homecare Settings
• Research Institutes

By Region

• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Rest of Europe

Elevate Your Business Strategy! Purchase the Report for Market-Driven Insights: https://www.transparencymarketresearch.com/checkout.php?rep_id=86308<ype=S

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com